NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




GI Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Colon

Alliance A021502 - "RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY OF PATIENTS WITH STAGE III COLON CANCER WITH DEFICIENT DNA MISMATCH REPAIR"

CANCER TYPE: Colon
RESEARCH BASE: Alliance
NCT NUMBER: NCT02912559
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Colon, Stage III, deficient DNA mismatch repair, completely resected,  mFOLFOX6 +/- Atezolizumab






Liver

RTOG 1112 - "RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA"

CANCER TYPE: Liver
RESEARCH BASE: NRG
NCT NUMBER: NCT01730937
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

HCC, BCLC stage Intermediate (B) or advanced (C), Sorafenib alone VS. SBRT + Sorafenib






Pancreas

Alliance A021501 - "PREOPERATIVE EXTENDED CHEMOTHERAPY VS. CHEMOTHERAPY PLUS HYPOFRACTIONATED RADIATION THERAPY FOR BORDERLINE RESECTABLE ADENOCARCINOMA OF THE HEAD OF THE PANCREAS"

CANCER TYPE: Pancreas
RESEARCH BASE: Alliance
NCT NUMBER: NCT02839343
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Head of pancreas, borderline resectable, T1-4, N0-1, Nx, M0, neo adjuvant chemo vs neo adjuvant chemo + RT






ECOG-ACRIN EA2142 - "Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas"

CANCER TYPE: Pancreas
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02595424
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

GI, locally advanced and unresectable, or metastatic, gastroenteropancreatic neuroendocrine non small cell carcinoma, Ki-67 20-100%, no brain mets.  Capecitabine and Temozolomide vs. Cisplatin (or Carboplatin) and Etoposide.






RTOG 0848 - "A Phase IIR and a Phase III Trial Evaluating Both Erlotinib (Ph IIR) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma"

CANCER TYPE: Pancreas
RESEARCH BASE: RTOG 0848
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

PANCREAS (Head), adenocarcinoma, resected, T1-3 N0-1 M0; Gemcitabine ---> (if no progression) Chemo +/- RT (Capecitabine or 5-FU) (Sites must be credentialed for 3D-CRT or IMRT - see protocol.)






SWOG S1505 - "A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma"

CANCER TYPE: Pancreas
RESEARCH BASE: SWOG
NCT NUMBER: NCT02562716
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Pancreas, resectable, adenoca, stage I or II. mFOLFIRINOX vs Gemcitabine and nab-Paclitaxel.






SWOG S1513 - "Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer"

CANCER TYPE: Pancreas
RESEARCH BASE: SWOG
NCT NUMBER: NCT02890355
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Pancreas adenoc, stage IV, mFOLFIRI + ABT-888 (Veliparib) vs FOLFIRI






Rectal

CTSU Alliance N1048 - "PROSPECT: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision"

CANCER TYPE: Rectal
RESEARCH BASE: CTSU Alliance N1048
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

RECTAL, adenocarcinoma, T2N1 T3N0 T3N1, candidate for sphincter-sparing resection prior to neo-adjuv therapy; Neo-adjuv FOLFOX + possible Combined Modality ChemoRT vs Combined Modality ChemoRT (both arms Low Anterior Resection [LAR] w/Total Mesorectal Excision [TME]). Credentialing required for 1) IMRT or 3D-CRT, & 2) staff member for PRO-CTCAE.









  © 2013-2017 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA